NEOGENOMICS INC — Director's Dealing 2025

Jun 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2025-06-01

Reporting Person: Zook Anthony P. (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-01	Common Stock	M	12254	—	Acquired	23590	Direct
2025-06-01	Common Stock	F	3424	—	Disposed	20166	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-01	Restricted Stock Unit	$0	M	12254	Disposed		Common Stock (12254)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18900	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$14.82	2033-08-10	Common Stock (8353)	8353	Direct
Stock Option (Right to Buy)	$13.71	2034-06-01	Common Stock (8672)	8672	Direct
Stock Option (Right to Buy)	$10.44	2035-04-01	Common Stock (729927)	729927	Direct
Restricted Stock Unit	$0		Common Stock (421496)	421496	Direct

Footnotes

F1: Reflects release of restricted stock units that were previously reported on a Form 4.

F2: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2024 vesting of restricted stock.

F3: Once vested, the shares of common stock are not subject to expiration.

F4: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.

F5: On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F6: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.